000650 仁和药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入2,833,452-10.07%4,074,8935,032,1465,153,2154,935,755
减:营业总成本2,337,881-9.84%3,362,2324,045,0634,208,2373,952,008
    其中:营业成本1,801,340-8.31%2,528,8813,164,0923,266,2773,061,415
               财务费用736-107.50%(10,312)(24,925)(23,065)(55,244)
               资产减值损失107-158.10%(113,320)(223,111)(68,739)(5,066)
公允价值变动收益(827)14.76%16,03416,82822,115(26)
投资收益38,33078.09%72,70259,26146,31431,475
    其中:对联营企业和合营企业的投资收益(2,939)-10.44%(4,831)(915)1,8036
营业利润616,982-10.05%774,986898,635953,2631,036,928
利润总额616,052-9.85%774,618898,860953,5401,034,418
减:所得税费用146,942-12.78%208,033269,450241,997234,545
净利润469,110-8.89%566,586629,410711,542799,874
减:非控股权益89,975-9.32%84,67462,153137,112134,849
股东净利润379,135-8.79%481,912567,257574,430665,025

市场价值指针
每股收益 (元) *0.271-8.79%0.3500.4100.4100.480
每股派息 (元) *----0.1500.2000.2000.100
每股净资产 (元) *4.5374.17%4.4104.2814.1013.777
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容